Cure My Disease

Don't miss your cure!

 Log in / Sign up

Second chance: can a different immunotherapy drug be safely retried after lung inflammation?

NCT ID NCT07775820

Disease control Sponsor: Nanfang Hospital, Southern Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This study looks at whether people with lung cancer who developed lung inflammation (pneumonitis) from immunotherapy can safely restart treatment with a different type of immunotherapy drug. Researchers will compare outcomes in patients who restart with a PD-L1 inhibitor, those who restart with a PD-1 inhibitor, and those who do not restart immunotherapy at all. The main focus is on whether the lung inflammation comes back, and the study also tracks other side effects and how well the cancer responds. This is an observational study, meaning doctors choose the treatment as part of routine care, and about 150 adults across multiple centers in China will take part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Restarting immunotherapy with a PD-L1 inhibitor or a PD-1 inhibitor after checkpoint inhibitor pneumonitis has resolved.
What this could lead to
If successful, this could help guide doctors on whether and how to safely resume immunotherapy in lung cancer patients who have experienced checkpoint inhibitor pneumonitis, potentially improving cancer control without unacceptable risks.
What could go wrong
This is an observational study, not a randomized trial, so results may be influenced by patient selection. Rechallenging with immunotherapy carries a risk of pneumonitis recurrence or other immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adults with histologically confirmed lung cancer who were treated with immune checkpoint inhibitor and subsequently developed checkpoint inhibitor pneumonitis. Eligible participants will be identified from participating centers in China and classified according to subsequent routine clinical management: PD-L1 inhibitor rechallenge, PD-1 inhibitor rechallenge, or no immune checkpoint inhibitor rechallenge. Both retrospective clinical records and prospective follow-up information will be collected.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18 years or older. 2. Histologically confirmed lung cancer. 3. Development of checkpoint inhibitor pneumonitis after treatment with immune checkpoint inhibitor. 4. Eastern Cooperative Oncology Group performance status of 0, 1, or 2. 5. Provision of written informed consent. Exclusion Criteria: 1. Incomplete clinical information required for the study analyses. 2. Considered unsuitable for participation by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Checkpoint inhibitor pneumonitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Checkpoint inhibitor pneumonitis Lung cancer Rechallenge

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Nanfang Hospital, Southern Medical University

    RECRUITING

    Guangzhou, Guangdong, 510400, China

  • Shenzhen People's Hospital

    RECRUITING

    Shenzhen, Guangdong, 518020, China

  • The First Affiliated Hospital of Guangzhou Medical University

    RECRUITING

    Guangzhou, Guangdong, 510030, China

  • The First Affiliated Hospital of Wenzhou Medical University

    RECRUITING

    Wenzhou, Zhejiang, 325088, China

  • The Second Affiliated Hospital of Nanchang University

    RECRUITING

    Nanchang, Jiangxi, 330200, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.